MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$5,447K
Free Cash flow
-$11,507K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sales and maturities of marketab...
Stock-based compensation
Proceeds from employee stock pur...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Accounts payable
Accretion of premiums/discounts ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-15,154
-14,456
-15,156
-12,792
Depreciation and amortization
134
83
85
81
Noncash operating lease expense
521
624
387
233
Stock-based compensation
3,840
3,823
2,482
2,569
Accretion of premiums/discounts on marketable securities, net
851
395
103
-4
Change in fair value of warrant liability
-
-
0
0
Loss on disposal of property and equipment
0
-2
0
-67
Gain on sale of equipment
-
-
-
0
Gain on marketable securities
0
0
6
0
Prepaid expenses and other current assets
-611
1,616
2,504
1,165
Other long-term assets
0
-
-9
0
Accounts payable
-990
490
162
-1,221
Accrued expenses
768
-3,525
2,097
351
Operating lease liabilities
-380
-1,296
-495
-257
Net cash used in operating activities
-11,501
-16,266
-13,042
-12,197
Purchase of property and equipment
6
312
42
98
Proceeds from sale of equipment
-
-
0
0
Purchases of marketable securities
45,785
97,117
84,733
18,641
Sales and maturities of marketable securities
50,645
58,121
37,322
33,680
Net cash provided by (used in) investing activities
4,854
-39,308
-47,453
14,941
Proceeds from issuance of common stock-IPO
-
-
0
0
Payments of deferred offering costs
53
69
0
80
Proceeds from issuance of common stock-At The Market Offering
-
-
0
19,012
Proceeds from issuance of common stock-Follow On Offering
-
-
93,243
-
Proceeds from exercise of stock options
473
198
22
173
Proceeds from employee stock purchase plan
780
-
200
0
Net cash provided by financing activities
1,200
129
93,465
19,105
Net decrease in cash and cash equivalents
-5,447
-55,445
32,970
21,849
Cash and cash equivalents at beginning of period
20,158
75,603
42,633
21,943
Cash and cash equivalents at end of period
14,711
20,158
75,603
42,633
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sales and maturities
of marketable...
$50,645K
(-42.46%↓ Y/Y)
Proceeds from employee
stock purchase plan
$780K
(192.13%↑ Y/Y)
Proceeds from exercise of
stock options
$473K
(1870.83%↑ Y/Y)
Net cash provided by
(used in) investing...
$4,854K
(-83.15%↓ Y/Y)
Net cash provided by
financing activities
$1,200K
(943.48%↑ Y/Y)
Canceled cashflow
$45,791K
Canceled cashflow
$53K
Net decrease in cash
and cash...
-$5,447K
(-369.97%↓ Y/Y)
Canceled cashflow
$6,054K
Stock-based compensation
$3,840K
(-23.00%↓ Y/Y)
Accrued expenses
$768K
(125.91%↑ Y/Y)
Prepaid expenses and
other current assets
-$611K
(-123.81%↓ Y/Y)
Noncash operating lease
expense
$521K
(13.26%↑ Y/Y)
Depreciation and
amortization
$134K
(-14.65%↓ Y/Y)
Purchases of marketable
securities
$45,785K
(-22.57%↓ Y/Y)
Purchase of property and
equipment
$6K
(-93.41%↓ Y/Y)
Payments of deferred
offering costs
$53K
(-69.89%↓ Y/Y)
Net cash used in
operating activities
-$11,501K
(61.76%↑ Y/Y)
Canceled cashflow
$5,874K
Net loss
-$15,154K
(52.69%↑ Y/Y)
Accounts payable
-$990K
(-621.05%↓ Y/Y)
Accretion of
premiums/discounts on marketable...
$851K
(22.98%↑ Y/Y)
Operating lease
liabilities
-$380K
(25.34%↑ Y/Y)
Buy us a coffee
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM)